• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

    3/8/23 5:30:00 PM ET
    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Computer Software: Prepackaged Software
    Technology
    Diversified Commercial Services
    Miscellaneous
    Get the next $BBAI alert in real time by email

    Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm The Briscoe Law Firm, PLLC are investigating potential violation of laws in connection with the following special purpose acquisition companies ("SPACs"): BigBear.ai Holdings, Inc. f/k/a GigCapital4 Inc. (NYSE:BBAI), Senti Biosciences, Inc. f/k/a Dynamics Special Purpose Corp (NASDAQGM:SNTI), Tango Therapeutics, Inc. f/k/a BCTG Acquisition Corp (NASDAQGM:TNGX), and Boxed, Inc. f/k/a Seven Oaks Acquisition Corp (NYSE:BOXD).

    If you are an affected investor, and you want to learn more about this investigation, please contact Willie Briscoe at The Briscoe Law Firm, PLLC, (972) 521-6868, or via email at [email protected]. There is no cost or fee to you.

    The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 23 years of experience in complex securities litigation and transactional matters.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005867/en/

    Get the next $BBAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBAI
    $BOXD
    $SNTI
    $TNGX

    CompanyDatePrice TargetRatingAnalyst
    Tango Therapeutics Inc.
    $TNGX
    4/3/2026$30.00Buy
    Canaccord Genuity
    Tango Therapeutics Inc.
    $TNGX
    4/2/2026$30.00Buy
    Canaccord Genuity
    Tango Therapeutics Inc.
    $TNGX
    2/23/2026$19.00Outperform
    Mizuho
    BigBear.ai Inc.
    $BBAI
    1/7/2026$6.00Overweight → Neutral
    Cantor Fitzgerald
    Tango Therapeutics Inc.
    $TNGX
    11/18/2025Peer Perform
    Wolfe Research
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Tango Therapeutics Inc.
    $TNGX
    8/19/2025$11.00Overweight
    Piper Sandler
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    More analyst ratings

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    SEC Filings

    View All

    SEC Form PRE 14A filed by BigBear.ai Inc.

    PRE 14A - BigBear.ai Holdings, Inc. (0001836981) (Filer)

    4/15/26 5:15:53 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Tango Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

    4/15/26 9:19:28 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by BigBear.ai Inc.

    DEFA14A - BigBear.ai Holdings, Inc. (0001836981) (Filer)

    4/10/26 4:15:26 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Crystal Adam

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    4/2/26 8:09:07 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ricker Sean Raymond

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    4/1/26 4:29:16 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Blankenship Carolyn

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    4/1/26 4:28:28 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $30.00

    4/3/26 10:44:59 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $30.00

    4/2/26 8:13:25 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Tango Therapeutics with a new price target

    Mizuho initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $19.00

    2/23/26 8:40:01 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

    -  Matthew Gall appointed Chief Financial Officer  --  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced key leadership appointments, adding three seasoned industry executives to the Company to support the rapid advancement of vopimetostat, a highly potent and selective PRMT5 inhibitor, towards its first potential regulatory approval in pancreatic cancer. Matthew Gall has been appointed Chief Financial O

    4/15/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

    SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, Co-Founder and Chief Executive Officer of Senti, will present at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA. Dr. Lu will participate in an educational session titled "Engineered NK Cells: From Innate Immunity to Clinical Innovation." The session will highlight advances in the development of Senti's engineered Logic-Gated SENTI-202 cell therapy and the broader potential for

    4/13/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BigBear.ai Announces Appointments of Jo Ann Bjornson as Chief Human Resources Officer and Alex Thompson as Chief Corporate Affairs Officer

    BigBear.ai (NYSE:BBAI), a specialized defense technology company, providing mission-ready AI for national security and travel & trade customers, today announced the appointment of Jo Ann Bjornson as Chief Human Resources Officer (CHRO) and Alex Thompson as Chief Corporate Affairs Officer (CCAO). These additions to the executive leadership team underscore BigBear.ai's commitment to driving growth, fostering innovation, and strengthening its position as a trusted partner in mission-critical environments. Jo Ann Bjornson joins BigBear.ai as CHRO, bringing over 25 years of experience in human resources leadership within federal contracting and commercial markets. Recognized as one of Washingt

    4/8/26 9:15:00 AM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    11/18/24 7:20:03 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Braden Pamela Joyce bought $209,999 worth of shares (140,939 units at $1.49), increasing direct ownership by 46% to 446,396 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    6/6/24 5:52:55 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Braden Pamela Joyce bought $96,048 worth of shares (50,025 units at $1.92), increasing direct ownership by 20% to 305,457 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    12/21/23 5:21:13 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/16/24 9:09:02 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/12/24 4:17:36 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/10/24 4:15:32 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Leadership Updates

    Live Leadership Updates

    View All

    BigBear.ai Announces Appointments of Jo Ann Bjornson as Chief Human Resources Officer and Alex Thompson as Chief Corporate Affairs Officer

    BigBear.ai (NYSE:BBAI), a specialized defense technology company, providing mission-ready AI for national security and travel & trade customers, today announced the appointment of Jo Ann Bjornson as Chief Human Resources Officer (CHRO) and Alex Thompson as Chief Corporate Affairs Officer (CCAO). These additions to the executive leadership team underscore BigBear.ai's commitment to driving growth, fostering innovation, and strengthening its position as a trusted partner in mission-critical environments. Jo Ann Bjornson joins BigBear.ai as CHRO, bringing over 25 years of experience in human resources leadership within federal contracting and commercial markets. Recognized as one of Washingt

    4/8/26 9:15:00 AM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n

    3/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

    Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a

    1/8/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

    SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, Co-Founder and Chief Executive Officer of Senti, will present at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA. Dr. Lu will participate in an educational session titled "Engineered NK Cells: From Innate Immunity to Clinical Innovation." The session will highlight advances in the development of Senti's engineered Logic-Gated SENTI-202 cell therapy and the broader potential for

    4/13/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

    SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the publication of new peer-reviewed research in Cell Systems demonstrating its systematic framework for engineering NOT-gated chimeric antigen receptor (CAR) circuits in both T cells and natural killer (NK) cells. The study demonstrates how Logic-Gated receptor designs can significantly improve the efficacy, precision, and safety of cell therapies by enabling immune cells to selectively eliminate tumor cells while sparing hea

    4/1/26 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2025 and full year 2025 and provided a summary of recent pipeline and corporate highlights. "2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform. Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENT

    3/27/26 8:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care